TANG CAPITAL MANAGEMENT LLC
13F Reported Value
ⓘ$2.2B
Holdings
41
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
TANG CAPITAL MANAGEMENT LLC disclosed 41 positions worth $2.2B in its Form 13F-HR for Q2 2026, led by $AUPH (Aurinia Pharmaceuticals Inc.) at 10.1% of the equity portfolio, followed by $SYRE and $MIRM. During the quarter the fund opened 5 new positions and exited 15 — including a new stake in $NVCT and a full exit from $KALV. The portfolio is most concentrated in Healthcare (89.7% of disclosed assets). All figures are sourced directly from TANG CAPITAL MANAGEMENT LLC’s Form 13F-HR filing with the SEC under CIK 1232621.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 75.2#101
Quality
$221.4M13,044,106 sh - —
Quality
$168.0M1,892,200 sh - 35.0#2,321
Quality
$144.7M1,236,027 sh - $144.5M2,259,889 sh
- —
Quality
$137.5M1,314,594 sh - 57.8
Quality
$130.4M1,500,000 sh - 35.4
Quality
$122.4M1,500,000 sh LAKEFRONT BIOTHERAPEUTICS NV - SPON ADR
—Quality
$113.5M3,785,991 sh- 13.6
Quality
$98.7M4,099,900 sh - 55.0
Quality
$98.7M1,568,266 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Aurinia Pharmaceuticals Inc.$AUPH | 75.2#101 | $221.4M | 13,044,106 |
 Spyre Therapeutics, Inc.$SYRE | — | $168.0M | 1,892,200 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0#2,321 | $144.7M | 1,236,027 |
 Kiniksa Pharmaceuticals International, plc$KNSA | — | $144.5M | 2,259,889 |
 Celcuity Inc.$CELC | — | $137.5M | 1,314,594 |
 CORCEPT THERAPEUTICS INC$CORT | 57.8 | $130.4M | 1,500,000 |
 PTC THERAPEUTICS, INC.$PTCT | 35.4 | $122.4M | 1,500,000 |
| LAKEFRONT BIOTHERAPEUTICS NV - SPON ADR | — | $113.5M | 3,785,991 |
 CAPRICOR THERAPEUTICS, INC.$CAPR | 13.6 | $98.7M | 4,099,900 |
 Tarsus Pharmaceuticals, Inc.$TARS | 55.0 | $98.7M | 1,568,266 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of TANG CAPITAL MANAGEMENT LLC's 41 positions.
Showing top 10 of 41 holdings.
Sector Allocation
Healthcare
$2.0B
Other
$205.4M
Technology
$20.7M
Full Holdings — TANG CAPITAL MANAGEMENT LLC (Q2 2026)
All 41 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AUPH | Aurinia Pharmaceuticals Inc. | $221.4M | 10.1% | +7% | 75.2 |
| 2 | $SYRE | Spyre Therapeutics, Inc. | $168.0M | 7.6% | +0% | — |
| 3 | $MIRM | Mirum Pharmaceuticals, Inc. | $144.7M | 6.6% | +0% | 35 |
| 4 | $KNSA | Kiniksa Pharmaceuticals International, plc | $144.5M | 6.6% | +0% | — |
| 5 | $CELC | Celcuity Inc. | $137.5M | 6.3% | +25% | — |
| 6 | $CORT | CORCEPT THERAPEUTICS INC | $130.4M | 5.9% | +0% | 57.8 |
| 7 | $PTCT | PTC THERAPEUTICS, INC. | $122.4M | 5.6% | +0% | 35.4 |
| 8 | — | LAKEFRONT BIOTHERAPEUTICS NV - SPON ADR | $113.5M | 5.2% | +0% | — |
| 9 | $CAPR | CAPRICOR THERAPEUTICS, INC. | $98.7M | 4.5% | +21% | 13.6 |
| 10 | $TARS | Tarsus Pharmaceuticals, Inc. | $98.7M | 4.5% | +32% | 55 |
| 11 |  $SPY | SPDR S&P 500 ETF TRUST | $91.9M | 4.2% | -27% | — |
| 12 |  $ANAB | ANAPTYSBIO, INC | $89.8M | 4.1% | +0% | 48.4 |
| 13 |  $IMCR | Immunocore Holdings plc | $84.1M | 3.8% | +0% | — |
| 14 |  $CMPS | COMPASS Pathways plc | $70.8M | 3.2% | +25% | — |
| 15 |  $ANIP | ANI PHARMACEUTICALS INC | $58.6M | 2.7% | +0% | 72.5 |
| 16 |  $BNTX | BioNTech SE | $43.7M | 2.0% | +0% | — |
| 17 |  $CMPX | Compass Therapeutics, Inc. | $39.4M | 1.8% | +7% | 28.1 |
| 18 |  $PGEN | PRECIGEN, INC. | $36.6M | 1.7% | +0% | 29.6 |
| 19 |  $VRDN | Viridian Therapeutics, Inc.\DE | $32.9M | 1.5% | +0% | 27.2 |
| 20 |  $NVCT | Nuvectis Pharma, Inc. | $28.5M | 1.3% | NEW | — |
| 21 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $25.8M | 1.2% | +0% | 22.6 |
| 22 |  $FULC | Fulcrum Therapeutics, Inc. | $23.9M | 1.1% | NEW | 32.9 |
| 23 |  $AVIR | Atea Pharmaceuticals, Inc. | $22.4M | 1.0% | +0% | — |
| 24 |  $CBIO | CRESCENT BIOPHARMA, INC. | $20.9M | 0.9% | +0% | 9.6 |
| 25 |  $NNDM | Nano Dimension Ltd. | $20.7M | 0.9% | NEW | — |
| 26 |  $VKTX | Viking Therapeutics, Inc. | $19.5M | 0.9% | +0% | — |
| 27 |  $NUVB | Nuvation Bio Inc. | $18.7M | 0.8% | +5% | 37.9 |
| 28 |  $IDYA | IDEAYA Biosciences, Inc. | $16.8M | 0.8% | +0% | 36.1 |
| 29 |  $GOSS | Gossamer Bio, Inc. | $11.5M | 0.5% | NEW | 8.2 |
| 30 |  $DERM | Journey Medical Corp | $11.4M | 0.5% | +0% | 16.5 |
| 31 |  $INSM | INSMED Inc | $10.7M | 0.5% | -62% | 39.4 |
| 32 |  $STOK | Stoke Therapeutics, Inc. | $9.8M | 0.5% | -40% | 24.9 |
| 33 |  $PLRX | PLIANT THERAPEUTICS, INC. | $7.0M | 0.3% | -0% | — |
| 34 |  $BOLD | Boundless Bio, Inc. | $6.4M | 0.3% | NEW | — |
| 35 |  $PMVP | PMV Pharmaceuticals, Inc. | $5.7M | 0.3% | +0% | — |
| 36 |  $MRNA | Moderna, Inc. | $3.5M | 0.2% | -50% | 21.2 |
| 37 |  $WVE | Wave Life Sciences, Inc. | $3.5M | 0.2% | +0% | 7.5 |
| 38 |  $HRTX | HERON THERAPEUTICS, INC. /DE/ | $2.7M | 0.1% | +0% | 24.7 |
| 39 |  $LENZ | LENZ Therapeutics, Inc. | $2.6M | 0.1% | +0% | 12.8 |
| 40 |  $ALT | Altimmune, Inc. | $2.0M | 0.1% | +0% | 8 |
| 41 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $342,000 | 0.0% | +0% | — |
New Positions (5)
Exited Positions (15)
$KALV KalVista Pharmaceuticals, Inc.
$JANX Janux Therapeutics, Inc.
$BIIB BIOGEN INC.
$URGN UroGen Pharma Ltd.
$ARVN ARVINAS, INC.
$KZR Kezar Life Sciences, Inc.
$AGIO AGIOS PHARMACEUTICALS, INC.
$ERAS Erasca, Inc.
$CHRS Coherus Oncology, Inc.
$NKTX Nkarta, Inc.
$EOLS Evolus, Inc.
$ABEO ABEONA THERAPEUTICS INC.
$FATE FATE THERAPEUTICS INC
$NMRA Neumora Therapeutics, Inc.
$LXRX LEXICON PHARMACEUTICALS, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for TANG CAPITAL MANAGEMENT LLC including:
Track TANG CAPITAL MANAGEMENT LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for TANG CAPITAL MANAGEMENT LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: TANG CAPITAL MANAGEMENT LLC
13F Pro is an AI hedge fund tracker and stock research platform. For TANG CAPITAL MANAGEMENT LLC (SEC CIK: 1232621), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in TANG CAPITAL MANAGEMENT LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.